AZTR (Azitra, Inc.) Forward P/S Multiple

Corporate emblem and logo of Azitra Corp (AZTR)

The implementation of automated bioreactors to eliminate contamination during protein synthesis is impacting share prices, and the forward P/S history on GURU.Markets reflects this trend, where 327.50 becomes the new value for the metric. Strategic alliances with research centers enhance the M&A attractiveness of Azitra, Inc., while the application of unique microbiome technologies allows the company to exercise pricing power by setting premium prices for dermatological drugs.

AZTR (Azitra) Price to Expected Revenue Ratio history from 03/17/2024 to 08/12/2025

Metric breakdowns and analytics for Azitra Corporation (AZTR)

- stock price and consensus target price:
Stock Quotes Azitra|AZTR - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization Azitra Corporation|AZTR - Company Buyout Price
- issuer book value statistics:
Accounting Value per Share Azitra|AZTR - Total Net Assets|Market Value to Book Value Ratio azitrainc.com|AZTR - Aggregate Asset Value
- company liabilities and liquidity data:
Total Debt to Capital Azitra, Inc.|AZTR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Azitra, Inc.|AZTR - Aggregate Debt Obligations|Debts to Book Capitalization Azitra Corporation|AZTR - Long-Term Debt Volume|Company Short-Term Debt Azitra|Quick Ratio azitrainc.com
- net income and valuation multiples indicators:
AZTR - Net Income|Future Profit Azitra, Inc.|AZTR - Business Payback Period|Forward P/E Multiple Azitra Corp|AZTR - PEG Multiple|Enterprise Value to EBITDA Ratio Azitra Corporation|AZTR - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Azitra|AZTR - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months azitrainc.com|AZTR - Earnings per share increase in current year|Net earnings per share growth forecast for next year Azitra, Inc.
- issuer revenue and sales details:
AZTR - Company Annual Revenue|Projected Sales Volume Azitra|AZTR - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Azitra Corporation
Summary company analysis:Azitra AZTR
Product sample of azitrainc.com

The forward P/S ratio compares the market capitalization of Azitra, Inc. (AZTR) with expected sales volume, allowing investors to determine the extent of the premium paid for future cash flows. By analyzing the forward P/S valuation, one can assess the fundamental value of the assets in the absence of geopolitical risks and sanctions pressure, which makes the multiplier's dynamics a pure reflection of the efficiency of developing skin microbiome-based drugs.

Analysis of competing companies

Krystal Biotech - Forward Price-to-Revenue Multiple|APGE (Apogee Therapeutics Inc) - Future Price to Revenue|Arcutis Biotherapeutics Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Vericel Inc. VCEL|ORKA (Oruka Therapeutics Inc) - Forward Price-to-Revenue Multiple|SMTI: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio DBV Tech|SLSN: Forward Price to Sales|Forward P/S Multiple DERM|Forward P/S Multiple Forte Biosciences Inc (FBRX)|Empro Group Inc - Forward Price-to-Revenue Multiple|Forward Price to Sales SLGL|Revive Pro Care - Forward P/S Multiple|Market Cap to Expected Sales Ratio Medicus Pharma Ltd MDCX|verrica.com (VRCA) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue HOTH|BFRI (Biofrontera, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple VYNE Therapeutics Inc (VYNE)|Forward Price-to-Revenue Multiple SNOA (Sonoma Pharmaceuticals)|Market Cap to Expected Sales Ratio quoinpharma.com|Forward P/S Multiple DRMA (Dermata)|Forward P/S Multiple Elevai Corp ELAB|RVNC: Forward Price-to-Revenue Multiple